New daily pill shows promise for weight loss in major trial

NCT ID NCT06693843

Ongoing Disease control Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 04, 2026 · Updated 21 times

Summary

This study tests an experimental daily pill, aleniglipron, to help people with obesity or overweight lose weight. About 220 adults will receive either the drug or a placebo for 36 weeks, followed by an optional 36-week extension where everyone gets the drug. The goal is to see how much weight is lost and if the pill is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY, OVERWEIGHT, OR CHRONIC WEIGHT MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

ACCESS Research Site

Phoenix, Arizona, 85044, United States
ACCESS Research Site

Anaheim, California, 92801, United States
ACCESS Research Site

Los Angeles, California, 90057, United States
ACCESS Research Site

Montclair, California, 91763, United States
ACCESS Research Site

Rancho Cucamonga, California, 91730, United States
ACCESS Research Site

Sacramento, California, 95821, United States
ACCESS Research Site

Spring Valley, California, 91978, United States
ACCESS Research Site

Honolulu, Hawaii, 96814, United States
ACCESS Research Site

Chicago, Illinois, 60602, United States
ACCESS Research Site

Chicago, Illinois, 60637, United States
ACCESS Research Site

Evanston, Illinois, 60201, United States
ACCESS Research Site

Muncie, Indiana, 47304, United States
ACCESS Research Site

Valparaiso, Indiana, 46383, United States
ACCESS Research Site

West Des Moines, Iowa, 50265, United States
ACCESS Research Site

Baton Rouge, Louisiana, 70808, United States
ACCESS Research Site

Richfield, Minnesota, 55423, United States
ACCESS Research Site

City of Saint Peters, Missouri, 63303, United States
ACCESS Research Site

Hazelwood, Missouri, 63042, United States
ACCESS Research Site

Springfield, Missouri, 65807, United States
ACCESS Research Site

Albany, New York, 12203, United States
ACCESS Research Site

Binghamton, New York, 13905, United States
ACCESS Research Site

Brooklyn, New York, 10016, United States
ACCESS Research Site

Rochester, New York, 14609, United States
ACCESS Research Site

Wilmington, North Carolina, 28403, United States
ACCESS Research Site

Cincinnati, Ohio, 45219, United States
ACCESS Research Site

Norman, Oklahoma, 73069, United States
ACCESS Research Site

Medford, Oregon, 97504, United States
ACCESS Research Site

Pittsburgh, Pennsylvania, 15236, United States
ACCESS Research Site

Moncks Corner, South Carolina, 29461, United States
ACCESS Research Site

Chattanooga, Tennessee, 37421, United States
ACCESS Research Site

Austin, Texas, 78704, United States
ACCESS Research Site

Austin, Texas, 78731, United States
ACCESS Research Site

Dallas, Texas, 75226, United States
ACCESS Research Site

Dallas, Texas, 75243, United States
ACCESS Research Site

Mesquite, Texas, 75149, United States
ACCESS Research Site

Shavano Park, Texas, 78231, United States
ACCESS Research Site

West Jordan, Utah, 84088, United States
ACCESS Research Site

Winchester, Virginia, 22601, United States
ACCESS Research Site

Morgantown, West Virginia, 26505, United States

Conditions

Explore the condition pages connected to this study.

OBESITY, OVERWEIGHT, OR CHRONIC WEIGHT MANAGEMENT